- Home
- JKS vs AUPH Comparison
JKS vs AUPH Comparison
Compare JKS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKS
- AUPH
- Stock Information
- Founded
- JKS 2006
- AUPH 1993
- Country
- JKS China
- AUPH Canada
- Employees
- JKS N/A
- AUPH N/A
- Industry
- JKS Semiconductors
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- JKS Technology
- AUPH Health Care
- Exchange
- JKS Nasdaq
- AUPH Nasdaq
- Market Cap
- JKS 1.3B
- AUPH 1.4B
- IPO Year
- JKS 2010
- AUPH 1999
- Fundamental
- Price
- JKS $26.10
- AUPH $12.63
- Analyst Decision
- JKS Sell
- AUPH Strong Buy
- Analyst Count
- JKS 4
- AUPH 3
- Target Price
- JKS $28.99
- AUPH $12.00
- AVG Volume (30 Days)
- JKS 550.6K
- AUPH 1.6M
- Earning Date
- JKS 10-29-2025
- AUPH 11-06-2025
- Dividend Yield
- JKS 5.67%
- AUPH N/A
- EPS Growth
- JKS N/A
- AUPH N/A
- EPS
- JKS N/A
- AUPH 0.42
- Revenue
- JKS $11,445,691,729.00
- AUPH $260,111,000.00
- Revenue This Year
- JKS N/A
- AUPH $16.92
- Revenue Next Year
- JKS $31.21
- AUPH $14.43
- P/E Ratio
- JKS N/A
- AUPH $30.61
- Revenue Growth
- JKS N/A
- AUPH 25.59
- 52 Week Low
- JKS $13.42
- AUPH $6.43
- 52 Week High
- JKS $37.36
- AUPH $12.90
- Technical
- Relative Strength Index (RSI)
- JKS 63.89
- AUPH 64.55
- Support Level
- JKS $23.60
- AUPH $12.06
- Resistance Level
- JKS $27.28
- AUPH $12.90
- Average True Range (ATR)
- JKS 1.13
- AUPH 0.36
- MACD
- JKS 0.21
- AUPH -0.04
- Stochastic Oscillator
- JKS 76.87
- AUPH 80.83
About JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.